healthcare

healthcare Articles

Melinta Therapeutics shares dropped on Monday despite the company announcing positive top-line results from its Phase 3 trial of Baxdela (delafloxacin) for the treatment of adult patients with...
Pfizer is scheduled to release its third-quarter financial results before the markets open on Tuesday.
Dicerna Pharmaceuticals and Eli Lilly are partnering up in a global licensing and research collaboration focused on the discovery, development and commercialization of potential new medicines in the...
Gilead shares retreated on Friday after it reported mixed third-quarter financial results late on Thursday.
The October 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
The October 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Alexion Pharmaceuticals reported better-than-expected quarterly results before the markets opened on Wednesday.
Biopharmaceutical company Orchard RX is offering more than 13 million shares in an initial public offering valued up to more than $245 million.
Pfizer, in collaboration with Bain Capital, announced the creation of Cerevel Therapeutics, a new biopharmaceutical company focused on developing drug candidates to treat disorders of the central...
Proteostasis Therapeutics shares pulled back on Tuesday after the company announced that it would be conducting a secondary offering.
Mirati shares dropped on Monday after the company announced updated positive clinical data from its midstage study in non-small cell lung cancer.
Medical technology company Axonics Modulation Technologies is offering more than 6 million shares in an initial public offering valued up to more than $122 million.
Here is a preview of some of the world’s largest players in the health care sector reporting earnings this coming week.
Clovis Oncology shares dropped on Friday after the company announced initial data from its Phase 2 clinical trial of Rubraca at the ESMO 2018 Congress.
Merrimack Pharmaceuticals shares dropped early on Friday after the company announced that it would be terminating its midstage SHERLOC study in patients with non-small cell lung cancer.